Mylan, U.S. finalize $465 million EpiPen settlement

Grassley calls deal 'a disappointment'

Jim Slosiarek/The Gazette

Sen Chuck Grassley says the settlement with Mylan in connection with claims it overcharged the federal government for its EpiPen “shortchanges the taxpayers.”
Jim Slosiarek/The Gazette Sen Chuck Grassley says the settlement with Mylan in connection with claims it overcharged the federal government for its EpiPen “shortchanges the taxpayers.”

BOSTON — Mylan NV has finalized a $465 million settlement resolving U.S. Justice Department claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.

The U.S. Attorney’s Office in Massachusetts on Thursday announced the accord, which soon after was criticized by some congressional members as being too easy on the drugmaker. It came 10 months after Mylan said it had reached a deal.

Iowa’s Sen. Chuck Grassley in a statement called the accord a “disappointment,” saying it “looks like the settlement amount shortchanges the taxpayers.”

The settlement resolved claims that Mylan avoided higher rebates to state Medicaid programs by misclassifying EpiPen as a generic product, even though it was marketed and priced as a brand-name product.

“Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules,” Acting U.S. Attorney William Weinreb said in a statement.

Under the deal, Mylan did not admit wrongdoing. It will reclassify EpiPen and pay the rebate applicable to its new classification as of April 1.

“Bringing closure to this matter is the right course of action for Mylan and our stakeholders to allow us to move forward,” Mylan CEO Heather Bresch said in a statement.

The deal followed a False Claims Act whistleblower lawsuit filed by French rival Sanofi SA in 2016, two years after it first raised the matter with authorities, Weinreb’s office said.

Sanofi, which formerly marketed a rival product called Auvi-Q, will receive nearly $38.8 million as a reward from the government.

Sanofi in a statement called pursuing the matter “the right thing to do.” It has a separate antitrust lawsuit pending alleging Mylan engaged in illegal conduct to squelch competition to EpiPen.

Mylan shares rose 2.10 percent to $31.11 on the Nasdaq.

The EpiPen, which Mylan acquired in 2007, is a handheld device that treats life-threatening allergic reactions by automatically injecting a dose of epinephrine.

Mylan came under fire last year after raising the price of a pair of EpiPens to $600, from $100 in 2008, enraging consumers and putting it in the center of the ongoing U.S. debate over the high cost of prescription medicines.

Mylan since has offered its own generic version for about $300. The company announced it had reached a Justice Department settlement in October.

Some congressional members previously criticized the $465 million settlement as too small. U.S. Sen. Richard Blumenthal, D-Conn., renewed that position on Thursday, calling it “completely insufficient.”

A U.S. Department of Health and Human Services’ Office of Inspector General analysis released in May found the U.S. government may have overpaid for EpiPens by up to $1.27 billion between 2006 and 2016.


“Absolving Mylan from a finding of wrongdoing has cleared the way for the company to pocket the money it embezzled from an American public in desperate need of lifesaving and affordable medications,” Blumenthal said in a statement.



WASHINGTON - In the end, it was neither the self-proclaimed deal making President Donald Trump nor seasoned congressional leaders who found a path to end - at least for now - the government shutdown.Rather, the agreement emerged f ...

WASHINGTON - Congress voted late Monday to reopen the government after a three-day shutdown, sending President Donald Trump a short-term spending bill that passed after Senate Republican leaders pledged to act on immigration polic ...

Give us feedback

Have you found an error or omission in our reporting? Tell us here.

Do you have a story idea we should look into? Tell us here.